1622. Minimally Invasive Sacroiliac Joint Fusion Using a Novel Hydroxyapatite-Coated Screw System Improves Functional Outcomes in Patients with Sacroilitis at One-Year Follow-up
Authors: Charles Ledonio; Alex Mohit, MD; Jessica Riggleman, BS; Amber Edsall, BS; Saif Khalil, PhD (Audubon, PA)
The sacroiliac joint (SIJ) has been implicated as a source of chronic low back pain in 15 to 30% of patients. The mainstay of therapy for disorders of the SIJ has been non-operative treatment, including activity modification, non-steroidal anti-inflammatory drugs, and physical therapy. SIJ injections provide diagnostic information and occasional durable therapeutic benefit. When these modalities fail, sacroiliac joint fusion may be recommended. This study describes the clinical outcomes of a novel hydroxyapatite-coated titanium screw for surgical treatment of SIJ dysfunction.
This study is a retrospective, Institutional Review Board-exempt chart review on 45 consecutive patients who underwent minimally invasive SIJ fusion with a novel hydroxyapatite-coated screw system. Patients were diagnosed based on North American Spine Society guidelines and evidence-based criteria. Clinical assessments were collected, evaluated, and compared pre-operatively and at 12 months post-operatively.
Mean patient age was 69.4±9.6 years, and 60.0% of patients were female. Mean preoperative visual analog scale sacroiliac (VAS SI) pain scores decreased significantly by a mean of 6.1 points at 12 months postoperatively (p<0.001). Oswestry Disability Index (ODI) scores significantly decreased by a mean of 41.4 points at 12 months postoperatively (p<0.001). Twenty percent (9/45) of patients underwent bilateral SIJ fusion, while the remaining were unilateral. Screw size ranged from 10x35 mm to 10x50 mm.
The clinical outcomes of SIJ fusion using a hydroxyapatite-coated screw system to treat sacroilitis significantly decreased VAS SI and ODI scores at 1 year.